Patent application number | Description | Published |
20100128834 | ZIRCONIUM ALLOYS WITH IMPROVED CORROSION RESISTANCE AND METHOD FOR FABRICATING ZIRCONIUM ALLOYS WITH IMPROVED CORROSION RESISTANCE - Articles, such as tubing or strips, which have excellent corrosion resistance to water or steam at elevated temperatures, are produced from alloys having 0.2 to 1.5 weight percent niobium, 0.01 to 0.45 weight percent iron, at least one additional alloy element selected from 0.02 to 0.8 weight percent tin, 0.05 to 0.5 weight percent chromium, 0.02 to 0.3 weight percent copper, 0.1 to 0.3 weight percent vanadium, 0.01 to 0.1 weight percent nickel, the balance at least 97 weight percent zirconium, including impurities, wherein the alloy may be fabricated from a process of forging the zirconium alloy into a material, beta quenching the material, forming the material by extruding or hot rolling the material, cold working the material with one or a multiplicity of cold working steps, wherein the cold working step includes cold reducing the material and annealing the material at an intermediate anneal temperature of 960°-1105° F., and final working and annealing of the material. The articles formed also show improved weld corrosion resistance with the addition of chromium. | 05-27-2010 |
20110293466 | ZIRCONIUM ALLOYS WITH IMPROVED CORROSION/CREEP RESISTANCE DUE TO FINAL HEAT TREATMENTS - Articles, such as tubing or strips, which have excellent corrosion resistance to water or steam at elevated temperatures, are produced from alloys having 0.2 to 1.5 weight percent niobium, 0.01 to 0.6 weight percent iron, and optionally additional alloy elements selected from the group consisting of tin, chromium, copper, vanadium, and nickel with the balance at least 97 weight percent zirconium, including impurities, where a necessary final heat treatment includes one of i) a SRA or PRXA (15-20% RXA) final heat treatment, or ii) a PRXA (80-95% RXA) or RXA final heat treatment. | 12-01-2011 |
20150307976 | ZIRCONIUM ALLOYS WITH IMPROVED CORROSION/CREEP RESISTANCE DUE TO FINAL HEAT TREATMENTS - The invention relates to zirconium-based alloys and articles produced therefrom, such as tubing or strips, which have at least one of excellent corrosion resistance to water or steam and creep resistance at elevated temperatures in a nuclear reactor. The alloys include from about 0.2 to 1.5 weight percent niobium, from about 0.01 to 0.6 weight percent iron, from about 0.0 to 0.8 weight percent tin, from about 0.0 to 0.5 weight percent chromium, from about 0.0 to 0.3 weight percent copper, from about 0,0 to 0.3 weight percent vanadium, and from about 0.0 to 0.1 weight percent nickel with the balance at least 97 weight percent zirconium, including impurities. Further, the articles are formed by processes that include final heat treatment of (i) SRA or PRXA (0-33% RXA), or (ii) RXA or PRXA (80-100% RXA). | 10-29-2015 |
Patent application number | Description | Published |
20120300063 | Droop Tester Apparatus and Method - The invention relates to a system for testing heart valve leaflets. The system includes a leaflet support assembly with a support post for receiving and supporting a leaflet to be tested, the post being disposed in a target region of the support assembly. The system also has a transmitter assembly that includes a light source and is configured and arranged to direct light from the light source onto the target region. The system further includes a receiver assembly that has an image sensor configured and arranged to sense an image of the target region and generate image information indicative of the sensed image, such as leaflet droop. | 11-29-2012 |
20140222144 | Anti-Paravalvular Leakage Component for a Transcatheter Valve Prosthesis - A transcatheter valve prosthesis includes an expandable tubular stent, a prosthetic valve within the stent, and an anti-paravalvular leakage component coupled to and encircling the tubular stent. The anti-paravalvular leakage component includes a radially-compressible annular scaffold, which is a sinusoidal patterned ring of self-expanding material, and an impermeable membrane extending over the annular scaffold. The anti-paravalvular leakage component has an expanded configuration in which at least segments of the annular scaffold curve radially away from the tubular stent. Alternatively, the anti-paravalvular leakage component includes a plurality of self-expanding segments and an annular sealing element coupled to inner surfaces of the segments. The anti-paravalvular leakage component has an expanded configuration in which the segments curve radially away from the tubular stent and the annular sealing element is positioned between an outer surface of the tubular stent and inner surfaces of the segments. | 08-07-2014 |
20140236287 | Transcatheter Valve Prosthesis and a Concurrently Delivered Sealing Component - A method of preventing paravalvular leakage includes concurrent delivery of a heart valve prosthesis and an annular sealing component. During delivery, the sealing component is moved from a first position to a second position of the heart valve prosthesis which is longitudinally spaced apart from the first position of the heart valve prosthesis. The sealing component is secured around the heart valve prosthesis at the second position by a contoured outer surface of the heart valve prosthesis. The sealing component may be a flexible ring or may be a cylindrical flexible sleeve having a plurality of ribs longitudinally extending over the cylindrical sleeve. The ribs operate to deploy the sealing component such that at least a portion of the cylindrical sleeve buckles outwardly away from the outer surface of the heart valve prosthesis. | 08-21-2014 |
20140277419 | Anti-Paravalvular Leakage Component for a Transcatheter Valve Prosthesis - A transcatheter valve prosthesis includes an expandable tubular stent, a prosthetic valve within the stent, and an anti-paravalvular leakage component coupled to and encircling the stent which includes a plurality of self-expanding struts and an annular sealing membrane. Each strut has a first end coupled to a distal end of the stent and a second end not coupled to the stent. Each anti-paravalvular leakage component is moveable between a compressed configuration and a deployed configuration. In the compressed configuration, each strut extends distally away from the distal end of the stent. In the deployed configuration, each strut extends proximally away from the distal end of the stent. In an embodiment hereof, the deployed strut has a C-shape and is twisted such that the C-shape lies in a plane substantially along or tangential with the outer surface of the stent. In another embodiment hereof, the deployed strut is rolled-up and extends radially away from the outer surface of the stent. | 09-18-2014 |
Patent application number | Description | Published |
20080200393 | Method and Composition For Treating Angiogenesis and For Preventing Cancer Progression and Metastasis Comprising a Prostate Secretory Protein (Psp94) Family Member - Angiogenesis, the formation of new blood vessels, is an integral part of normal physiological and developmental processes as well as several pathologies, ranging from tumor growth and metastasis to inflammation and ocular disease. Methods and compositions are provided for controlling normal angiogenesis and for treating angiogenesis associated or mediated diseases as well as for preventing cancer progression and metastasis through the use of a prostrate secretory protein (PSP) family member. | 08-21-2008 |
20100239653 | PHARMACEUTICAL PREPARATIONS AND METHODS FOR INHIBITING TUMORS - The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH). In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer. The anticancer drug of the latter mixture may be one selected from the group of drugs including mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof. | 09-23-2010 |
Patent application number | Description | Published |
20080302364 | System and Method for Treating Ventilatory Instability - A therapy system adapted to treat a patient's ventilatory instability using a ventilatory therapy, a gas modulation therapy, or both. The algorithm implemented by the therapy system monitors the ventilatory instability, such as Cheyne Stokes Respiration (CSR), mixed apneas, CPAP emergent apneas, and complex sleep disordered breathing (CSDB) and treats the ventilatory instability. The algorithm also determine a reference point with respect to the ventilatory instability. The therapy delivery system initiate the treatment based on the reference point. | 12-11-2008 |
20110220107 | INSUFFLATING-EXSUFFLATING SYSTEM | 09-15-2011 |
20120199127 | SYSTEM AND METHOD FOR SUCTIONING FOR SECRETION REMOVAL FROM THE AIRWAY OF A MECHANICALLY VENTILATED SUBJECT - Secretions that have accumulated at or near an airway of a subject ( | 08-09-2012 |
20120209089 | SYSTEM AND METHOD FOR TREATING DYSPHAGIA - Dysphagia of a subject ( | 08-16-2012 |
20130133654 | SYSTEM AND METHOD FOR PROVIDING A PRESSURIZED FLOW OF BREATHABLE GAS TO THE AIRWAY OF A SUBJECT WITH STOCHASTIC FLUCTUATIONS - A pressurized flow of breathable gas is delivered to the airway of a subject to facilitate respiration by the subject. To enhance the effectiveness of the pressurized flow of breathable gas, stochastic fluctuations in the level of pressure at or near the airway of the subject are created. These stochastic fluctuations mimic similar oscillations present in so-called “bubble CPAP” systems. Since these stochastic fluctuations are intended to maintain the openness of the airway of the subject, and not to drive ventilation, these fluctuations tend to have a higher frequency and/or lower magnitude than changes in pressure that drive ventilation. | 05-30-2013 |
20130133655 | SYSTEM AND METHOD FOR SUPPORTING SUB-PHYSIOLOGIC AND PHYSIOLOGIC TIDAL VOLUMES IN SPONTANEOUS OR NON-SPONTANEOUS BREATHING DURING HIGH FREQUENCY VENTILATION - A method of providing high frequency ventilation to a patient, comprises delivering a flow of breathing gas to the patient, the flow of breathing gas having a first positive pressure level and a second positive pressure level, the first and second positive pressure levels alternating with one another in a plurality of cycles in the flow of breathing gas to have a frequency and an amplitude, the flow of breathing gas to the patient generating a mean airway pressure; determining whether the patient is breathing spontaneously or is trying to breath spontaneously; and, in response to the determination that the patient is breathing spontaneously or trying to breath spontaneously or according to the user settings for HFV and user intervention for non-spontaneous breathing patient, adjusting the mean airway pressure, modulating the frequency and duty cycle of the flow of breathing gas, or modulating the level of flow and pressure amplitude of the breathing gas, or two or more thereof. | 05-30-2013 |
20130263845 | HUMIDIFIER SYSTEM FOR HUMIDIFYING GAS DELIVERED TO A PATIENT - Provided are systems and methods for humidifying gas to be provided to a patient utilizing heating of an aerosolized mist. A humidification unit ( | 10-10-2013 |
20130263851 | SYSTEM AND METHOD FOR ADMINISTERING HUMIDIFIED GAS TO A VENTILATED PATIENT - Provided are systems for humidifying gas delivered to a patient. A humidifier unit ( | 10-10-2013 |
20130276789 | VENTILATOR WITH INTEGRATED BLOWER TO PROVIDE NEGATIVE OR POSITIVE PRESSURE IN A VENTILATOR SYSTEM - A ventilator system ( | 10-24-2013 |
20130312754 | SYSTEM AND METHOD FOR CUSTOMIZABLE AUTOMATED CONTROL OF FRACTION OF INSPIRED OXYGEN AND/OR POSITIVE END EXPIRATORY PRESSURE TO MAINTAIN OXYGENATION - A pressurized flow of breathable gas is delivered to the airway of a subject in accordance with a therapy regimen. The therapy regimen may be designed to maintain oxygenation of the subject. The therapy regimen dictates levels of fraction of inspired oxygen and/or positive end expiratory pressure to maintain a therapeutically beneficial level of oxygenation in a feedback manner. Within the therapy regimen, changes made to fraction of inspired oxygen and/or positive end expiratory pressure automatically and dynamically are constrained by user configured constraints such as the maximum incremental change, amount of time between adjustments, or the maximum rate of change This may provide a level of customization of the automated control of the therapy regime for individual subjects. | 11-28-2013 |
20140202455 | METHOD AND APPARATUS FOR CONTROLLING A VENTILATION THERAPY DEVICE - A method and apparatus provide closed-loop control of the operation of a ventilator device based on physiological parameters received from and/or through a patient monitor device, which is a separate and discrete device from the ventilator device. | 07-24-2014 |
20140261416 | THERMAL COOLER & DEHUMIDIFIER FOR EXHALATION PATH IN VENTILATOR SYSTEM - A ventilator system ( | 09-18-2014 |
20150027445 | SYSTEMS AND METHODS FOR INTRA-PULMONARY PERCUSSIVE VENTILATION INTEGRATED IN A VENTILATOR - System and methods for providing respiratory therapy include predetermined and/or automatically determined perturbations of levels of pressure, flow, and/or other gas parameters integrated and/or combined (Start with a supplied pressurized flow of breathable gas for a subject. The perturbations are intended to improve secretion management through intra-pulmonary percussive ventilation integrated with ventilation therapy. | 01-29-2015 |